Microbix Biosystems Inc. (MBXBF)

USD 0.25

(0.0%)

Market Cap (In USD)

33.49 Million

Revenue (In USD)

16.51 Million

Net Income (In USD)

-39.48 Thousand

Avg. Volume

10.29 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.2-0.328
PE
-
EPS
-
Beta Value
0.343
ISIN
CA59501P1045
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Cameron L. Groome
Employee Count
-
Website
https://microbix.com
Ipo Date
2021-01-08
Details
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.